INT100689

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 11
Disease Relevance 5.36
Pain Relevance 1.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (JAK1) cytoskeleton (JAK1) nucleus (JAK1)
cytoplasm (JAK1)
JAK1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 107 99.52 Very High Very High Very High
rheumatoid arthritis 89 98.64 Very High Very High Very High
cytokine 164 98.04 Very High Very High Very High
Inflammation 148 96.44 Very High Very High Very High
psoriasis 12 93.00 High High
Arthritis 202 91.48 High High
Paracetamol 4 79.88 Quite High
aspirin 14 78.32 Quite High
addiction 2 32.92 Quite Low
agonist 3 30.80 Quite Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 89 98.64 Very High Very High Very High
Autoimmune Disease 5 97.20 Very High Very High Very High
Leiomyosarcoma 118 96.48 Very High Very High Very High
INFLAMMATION 158 96.44 Very High Very High Very High
Cancer 88 95.76 Very High Very High Very High
Psoriasis 12 93.00 High High
Renal Failure 11 92.04 High High
Thrombosis 13 91.76 High High
Disease 113 91.56 High High
Arthritis 218 91.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As we look at MPD therapeutic goals (Figure 1), will inhibition of the JAK-STAT pathway decrease myelo-proliferation?
Negative_regulation (inhibition) of JAK
1) Confidence 0.57 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 0.28 Pain Relevance 0
As we look at MPD therapeutic goals (Figure 1), will inhibition of the JAK-STAT pathway decrease myelo-proliferation?
Negative_regulation (decrease) of JAK
2) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 0.29 Pain Relevance 0
Among the most intriguing genes, whose copy number sequence was revealed by CGH, were loss of JAK1 (1p31~p32) and LMP2 (6p21.3) (Lee et al. 2006; Svarvar et al. 2006).
Negative_regulation (loss) of JAK1
3) Confidence 0.41 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733082 Disease Relevance 0.56 Pain Relevance 0
The growth of the original SKN cells, which had defective JAK1 activity, was unaffected by IFN-?
Negative_regulation (defective) of JAK1
4) Confidence 0.30 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733082 Disease Relevance 0.40 Pain Relevance 0
In one study, Rat VSMC were stimulated with IL-6 in the presence or absence of a JAK 2 inhibitor, and the activation of STAT 3 (by Western), MCP-1 (by ELISA) and DNA synthesis (by (3)H-thymidine incorporation) was determined.
Negative_regulation (inhibitor) of JAK
5) Confidence 0.16 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 0.41 Pain Relevance 0
Furthermore, we found that an Src kinase was involved in STAT6 activation because 1) Src kinase activity was induced by IL-4, 2) Src kinase activity, but not Janus kinase, was inhibited by salicylates in vitro, 3) cells expressing viral Src had constitutive STAT6 phosphorylation, and 4) cells lacking Src showed low STAT6 phosphorylation in response to IL-4.
Negative_regulation (inhibited) of Janus kinase
6) Confidence 0.10 Published 2002 Journal J. Immunol. Section Abstract Doc Link 11801685 Disease Relevance 0.65 Pain Relevance 0.25
Additionally, we used pharmacokinetic and pharmacodynamic (PK/PD) modeling to determine the exposure-effect relationships and correlations between JAK inhibition, efficacy and PBNC reductions in both the non-clinical models and in RA patient populations.
Negative_regulation (reductions) of JAK associated with rheumatoid arthritis
7) Confidence 0.03 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2928212 Disease Relevance 1.11 Pain Relevance 0.56
Since JAKs directly phosphorylate STAT proteins in response to specific cytokine stimulation, measuring the extent of STAT phosphorylation in cells is an indirect measurement of JAK inhibition.
Negative_regulation (inhibition) of JAK associated with cytokine
8) Confidence 0.03 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2928212 Disease Relevance 0 Pain Relevance 0.31
CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.
Negative_regulation (inhibitor) of JAK associated with autoimmune disease and rheumatoid arthritis
9) Confidence 0.03 Published 2010 Journal J Inflamm (Lond) Section Abstract Doc Link PMC2928212 Disease Relevance 0.55 Pain Relevance 0.34
CP-690,550, a selective inhibitor of the JAK family of protein tyrosine kinases, is being developed as an immunosuppressive and anti-inflammatory agent for the treatment and prevention of acute allograft rejection, RA, psoriasis and other immune mediated diseases [1-6].
Negative_regulation (inhibitor) of JAK associated with psoriasis, inflammation, rheumatoid arthritis and disease
10) Confidence 0.03 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2928212 Disease Relevance 0.73 Pain Relevance 0.32
A number of JAK inhibitors, with varying degrees of specificity for JAK-3, are under investigation [130, 131].
Negative_regulation (inhibitors) of JAK
11) Confidence 0.02 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.34 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox